VANCOUVER, BC / ACCESSWIRE / October 3, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT), announces that Per Thoresen and Peter Damouni have resigned as directors of the Company. The Company would like to thank Mr. Thoresen and Mr. Damouni for their contributions to the Company.
The Company is pleased to also announce that Joseph Meagher, the Chief Financial Officer of the Company, has been appointed as a director of the Company to fill one of the vacancies.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next‐generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low‐cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets
BioNxt Solutions Inc.
Hugh Rogers, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
| Last Trade: | C$0.43 |
| Daily Change: | -0.005 -1.15 |
| Daily Volume: | 15,500 |
| Market Cap: | C$48.760M |
February 24, 2025 January 21, 2025 December 19, 2024 December 09, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
